Exploring the link between MORF4L1 and risk of breast cancer
Griselda Martrat(Institut d'Investigació Biomédica de Bellvitge), Laura Ottini(Mount Sinai Hospital), Jackie Cook(Sheffield Children's Hospital), Gonzalo Hernández(Universitat Autònoma de Barcelona), Rosalind A. Eeles(Royal Marsden NHS Foundation Trust), Montserrat Porta-de-la-Riva(Institut d'Investigació Biomédica de Bellvitge), Julia Kühl(University of Würzburg), María Castellà(Hospital Clínic de Barcelona), Barbara Pasini(University of Turin), Siranoush Manoukian(Fondazione IRCCS Istituto Nazionale dei Tumori), Laia Gómez‐Baldó(Bellvitge University Hospital), Louise Izatt(Guy's and St Thomas' NHS Foundation Trust), Douglas F. Easton(University of Cambridge), Emiko Tominaga(The University of Texas at San Antonio Health Science Center), Christopher A. Maxwell(University of British Columbia), Gaia Roversi, Patrick J. Morrison(Belfast Health and Social Care Trust), Núria Bonifaci(Bellvitge University Hospital), Joan Brunet(Institut Català d'Ornitologia), Juana Fernández‐Rodríguez(Institut d'Investigació Biomédica de Bellvitge), Daniela Zaffaroni(Fondazione IRCCS Istituto Nazionale dei Tumori), Marı́a José Ramı́rez(Universitat Autònoma de Barcelona), Conxi Lázaro(Institut d'Investigació Biomédica de Bellvitge), Ignacio Blanco(Hospital Universitari Germans Trias i Pujol), Carol Chu(Lyon 1 Université), Bernard Peissel(Sapienza University of Rome), D. Gareth Evans(Manchester Academic Health Science Centre), Massimo Bogliolo(Universitat Autònoma de Barcelona), Nazneen Rahman(Institute of Cancer Research), Margaret Cook(Cancer Research UK), Clare T Oliver(University of Cambridge), Paolo Peterlongo(IFOM), Anthony Renwick(Institute of Cancer Research), Monica Barile(European Institute of Oncology), Mary Porteous(University of Edinburgh), Fiona Douglas(University of Southern California), Sheila Seal(Institute of Cancer Research), Radka Platte(University of Cambridge), Kai-Ren Ong(Birmingham Women's Hospital), Rosemarie Davidson(The Netherlands Cancer Institute), Carole Brewer(Royal Devon and Exeter Hospital), Susan Peock(Cancer Research UK), Fiona Lalloo(Manchester Academic Health Science Centre), Shirley Hodgson(St Thomas' Hospital), Helena Aguilar(Bellvitge University Hospital), Debra Frost(University of Cambridge), Detlev Schindler(University of Würzburg), Alessandra Viel(Centro di Riferimento Oncologico), Kornelia Neveling(University of Würzburg)
Cited by 28
Related Papers
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
The evolutionary history of lethal metastatic prostate cancer
|Nature|2015|1.4k